Organization
NEXT Oncology, San Antonio, TX
4 abstracts
Abstract
A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer.Org: National Cancer Center Hospital East, Chiba, Japan, Samsung Medical Center, Seoul, seoul, South Korea, NEXT Oncology, San Antonio, TX, National Cancer Center Hospital, Tokyo, Japan, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea,
Abstract
A phase I/II, open-label, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of HB0036 in patients with advanced solid tumors.Org: NEXT Oncology, San Antonio, TX, Horizon Oncology Research LLC, Lafayette, IN, Summit Cancer Centers, Spokane Valley, WA, Huaota Biopharma Co., Ltd., Shanghai, China, Huaota Biopharm Co., Ltd., Shanghai, China,
Abstract
Phase 1 trial of a novel C’Dot drug conjugate (CDC), ELU001, in patients with solid tumors known to overexpress folate receptor alpha (FRα).Org: Division of Medical Oncology, Mayo Clinic, Rochester, MN, NEXT Oncology, San Antonio, TX, Sarah Cannon Research Institute at Florida Cancer Specialists, Lake Nona, FL, Mary Crowley Cancer Research, Dallas, TX, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN,
Abstract
A phase 2 study of alrizomadlin (APG-115) in combination with pembrolizumab in patients with unresectable or metastatic cutaneous melanoma that has failed immuno-oncologic (IO) drugs.Org: University of Texas Health Science Ctr, San Antonio, TX, The University of Arizona Cancer Center, Tucson, AZ, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, Penn State Hershey Medical Center Cancer Institute, Hershey, PA, Sarah Cannon Research Institute at Tennessee Oncology, PLLC, Nashville, TN,